Log In Get Started
Press Releases April 30, 2026 04:45 PM

Smithfield Foods Declares Quarterly Dividend

Smithfield Foods Announces Quarterly Dividend to Reward Shareholders

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
SFD

Smithfield Foods, a major American packaged meats company, declared a quarterly dividend of $0.3125 per share, payable on May 28, 2026, to shareholders of record by May 14, 2026. This move reflects the company's stable financial position and commitment to returning value to its investors.

Smithfield Foods Declares Quarterly Dividend
SFD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Smithfield Foods declared a quarterly dividend of $0.3125 per share.
  • Dividend payable on May 28, 2026, to shareholders of record on May 14, 2026.
  • Company maintains strong market position in packaged meats and fresh pork products in the US.

SMITHFIELD, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Smithfield Foods, Inc. (Nasdaq: SFD), an American food company and an industry leader in value-added packaged meats and fresh pork, today announced its Board of Directors approved a quarterly dividend payment of $0.3125 per share of common stock to be paid on May 28, 2026 to shareholders of record at the close of business on May 14, 2026.

About Smithfield Foods
Smithfield Foods, Inc. (Nasdaq: SFD) is an American food company with a leading position in packaged meats and fresh pork products. With a diverse brand portfolio and strong relationships with U.S. farmers and customers, we responsibly meet demand for quality protein around the world.

Investor Contact:
Julie MacMedan
Email: ir@smithfield.com

Media Contact:
Ray Atkinson
Email: ratkinson@smithfield.com
Cell: 757.576.1383


Risks

  • Dividend payments depend on continued profitability and cash flow, which may be affected by market conditions.
  • Potential fluctuations in agricultural commodity prices could impact company margins.
  • Regulatory changes in the food industry could affect operational costs and dividend sustainability.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026